Specific adducts recognised by a monoclonal antibody against cisplatin-modified DNA

Numerous clinical or experimental studies have employed monoclonal antibody CP9/19 for quantification of cisplatin DNA adducts. The nature of adducts recognised by CP9/19 on polymeric DNA were defined using synthetic deoxynucleotides reacted with cisplatin. Total adduct levels were determined by ato...

Full description

Saved in:
Bibliographic Details
Published inBiochemical pharmacology Vol. 70; no. 12; pp. 1717 - 1725
Main Authors Meczes, Emma L., Azim-Araghi, Ali, Ottley, Christopher J., Pearson, D. Graham, Tilby, Michael J.
Format Journal Article
LanguageEnglish
Published New York, NY Elsevier Inc 05.12.2005
Elsevier Science
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Numerous clinical or experimental studies have employed monoclonal antibody CP9/19 for quantification of cisplatin DNA adducts. The nature of adducts recognised by CP9/19 on polymeric DNA were defined using synthetic deoxynucleotides reacted with cisplatin. Total adduct levels were determined by atomic absorption spectrometry. The nature of adducts formed were confirmed by analysis of enzymatic hydrolysates using an established ion-exchange chromatography method combined with inductively coupled plasma mass spectrometry. Of the Pt bound to oligonucleotide A (TTTTTGGTTTTTGGTTTTTGGTTTTTGGTTTTT), 77% was recovered in a product consistent with the expected 1,2 intra-strand cross-link between GG. For oligonucleotide B (TTTTTAGTTTTTAGTTTTTAGTTTTTAGTTTTT), 62% of the bound Pt was recovered in a product consistent with the 1,2 intra-strand cross-link between AG. Of Pt bound to oligothymydylic acid, 65% was recovered in a product not previously described, small quantities of which were also formed on oligonucleotides A and B. The concentrations of adducts required to cause 50% reduction of signal in a competitive enzyme-linked immunosorbant assay (ELISA) ( K-values) were determined. Adducts on sequences containing no guanine or only non-adjacent guanine residues, including sequences containing adenines adjacent to guanines, exhibited low or undetectable immunoreactivities ( K-values = from 1 to >100 pmoles Pt per assay well). Adducts formed on oligodeoxynucleotides containing guanine doublets interspersed amongst thymine residues were the most immunoreactive ( K-values: 2–7 fmoles adduct per assay well), comparable to adducts on calf-thymus DNA. The only cisplatin–DNA adducts recognised with high sensitivity by antibody CP9/19 were those involving adjacent guanine residues but immunorecognition of these was influenced by the surrounding DNA sequence.
AbstractList Numerous clinical or experimental studies have employed monoclonal antibody CP9/19 for quantification of cisplatin DNA adducts. The nature of adducts recognised by CP9/19 on polymeric DNA were defined using synthetic deoxynucleotides reacted with cisplatin. Total adduct levels were determined by atomic absorption spectrometry. The nature of adducts formed were confirmed by analysis of enzymatic hydrolysates using an established ion-exchange chromatography method combined with inductively coupled plasma mass spectrometry. Of the Pt bound to oligonucleotide A (TTTTTGGTTTTTGGTTTTTGGTTTTTGGTTTTT), 77% was recovered in a product consistent with the expected 1,2 intra-strand cross-link between GG. For oligonucleotide B (TTTTTAGTTTTTAGTTTTTAGTTTTTAGTTTTT), 62% of the bound Pt was recovered in a product consistent with the 1,2 intra-strand cross-link between AG. Of Pt bound to oligothymydylic acid, 65% was recovered in a product not previously described, small quantities of which were also formed on oligonucleotides A and B. The concentrations of adducts required to cause 50% reduction of signal in a competitive enzyme-linked immunosorbant assay (ELISA) (K-values) were determined. Adducts on sequences containing no guanine or only non-adjacent guanine residues, including sequences containing adenines adjacent to guanines, exhibited low or undetectable immunoreactivities (K-values = from 1 to >100 pmoles Pt per assay well). Adducts formed on oligodeoxynucleotides containing guanine doublets interspersed amongst thymine residues were the most immunoreactive (K-values: 2-7 fmoles adduct per assay well), comparable to adducts on calf-thymus DNA. The only cisplatin-DNA adducts recognised with high sensitivity by antibody CP9/19 were those involving adjacent guanine residues but immunorecognition of these was influenced by the surrounding DNA sequence.
Numerous clinical or experimental studies have employed monoclonal antibody CP9/19 for quantification of cisplatin DNA adducts. The nature of adducts recognised by CP9/19 on polymeric DNA were defined using synthetic deoxynucleotides reacted with cisplatin. Total adduct levels were determined by atomic absorption spectrometry. The nature of adducts formed were confirmed by analysis of enzymatic hydrolysates using an established ion-exchange chromatography method combined with inductively coupled plasma mass spectrometry. Of the Pt bound to oligonucleotide A (TTTTTGGTTTTTGGTTTTTGGTTTTTGGTTTTT), 77% was recovered in a product consistent with the expected 1,2 intra-strand cross-link between GG. For oligonucleotide B (TTTTTAGTTTTTAGTTTTTAGTTTTTAGTTTTT), 62% of the bound Pt was recovered in a product consistent with the 1,2 intra-strand cross-link between AG. Of Pt bound to oligothymydylic acid, 65% was recovered in a product not previously described, small quantities of which were also formed on oligonucleotides A and B. The concentrations of adducts required to cause 50% reduction of signal in a competitive enzyme-linked immunosorbant assay (ELISA) (K-values) were determined. Adducts on sequences containing no guanine or only non-adjacent guanine residues, including sequences containing adenines adjacent to guanines, exhibited low or undetectable immunoreactivities (K-values = from 1 to >100 pmoles Pt per assay well). Adducts formed on oligodeoxynucleotides containing guanine doublets interspersed amongst thymine residues were the most immunoreactive (K-values: 2-7 fmoles adduct per assay well), comparable to adducts on calf-thymus DNA. The only cisplatin-DNA adducts recognised with high sensitivity by antibody CP9/19 were those involving adjacent guanine residues but immunorecognition of these was influenced by the surrounding DNA sequence.
Numerous clinical or experimental studies have employed monoclonal antibody CP9/19 for quantification of cisplatin DNA adducts. The nature of adducts recognised by CP9/19 on polymeric DNA were defined using synthetic deoxynucleotides reacted with cisplatin. Total adduct levels were determined by atomic absorption spectrometry. The nature of adducts formed were confirmed by analysis of enzymatic hydrolysates using an established ion-exchange chromatography method combined with inductively coupled plasma mass spectrometry. Of the Pt bound to oligonucleotide A (TTTTTGGTTTTTGGTTTTTGGTTTTTGGTTTTT), 77% was recovered in a product consistent with the expected 1,2 intra-strand cross-link between GG. For oligonucleotide B (TTTTTAGTTTTTAGTTTTTAGTTTTTAGTTTTT), 62% of the bound Pt was recovered in a product consistent with the 1,2 intra-strand cross-link between AG. Of Pt bound to oligothymydylic acid, 65% was recovered in a product not previously described, small quantities of which were also formed on oligonucleotides A and B. The concentrations of adducts required to cause 50% reduction of signal in a competitive enzyme-linked immunosorbant assay (ELISA) ( K-values) were determined. Adducts on sequences containing no guanine or only non-adjacent guanine residues, including sequences containing adenines adjacent to guanines, exhibited low or undetectable immunoreactivities ( K-values = from 1 to >100 pmoles Pt per assay well). Adducts formed on oligodeoxynucleotides containing guanine doublets interspersed amongst thymine residues were the most immunoreactive ( K-values: 2–7 fmoles adduct per assay well), comparable to adducts on calf-thymus DNA. The only cisplatin–DNA adducts recognised with high sensitivity by antibody CP9/19 were those involving adjacent guanine residues but immunorecognition of these was influenced by the surrounding DNA sequence.
Author Azim-Araghi, Ali
Meczes, Emma L.
Ottley, Christopher J.
Pearson, D. Graham
Tilby, Michael J.
Author_xml – sequence: 1
  givenname: Emma L.
  surname: Meczes
  fullname: Meczes, Emma L.
  organization: Northern Institute for Cancer Research, Paul O’Gorman Building, Medical School, University of Newcastle, Framlington Place, Newcastle Upon Tyne NE2 4HH, UK
– sequence: 2
  givenname: Ali
  surname: Azim-Araghi
  fullname: Azim-Araghi, Ali
  organization: Northern Institute for Cancer Research, Paul O’Gorman Building, Medical School, University of Newcastle, Framlington Place, Newcastle Upon Tyne NE2 4HH, UK
– sequence: 3
  givenname: Christopher J.
  surname: Ottley
  fullname: Ottley, Christopher J.
  organization: Arthur Holmes Isotope Geology Laboratory, Department of Earth Sciences, University of Durham, Science Laboratories, South Road, Durham City DH1 3LE, UK
– sequence: 4
  givenname: D. Graham
  surname: Pearson
  fullname: Pearson, D. Graham
  organization: Arthur Holmes Isotope Geology Laboratory, Department of Earth Sciences, University of Durham, Science Laboratories, South Road, Durham City DH1 3LE, UK
– sequence: 5
  givenname: Michael J.
  surname: Tilby
  fullname: Tilby, Michael J.
  email: M.J.Tilby@ncl.ac.uk
  organization: Northern Institute for Cancer Research, Paul O’Gorman Building, Medical School, University of Newcastle, Framlington Place, Newcastle Upon Tyne NE2 4HH, UK
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17302427$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/16259963$$D View this record in MEDLINE/PubMed
BookMark eNp9kMFq3DAQhkVJaHbTPEAvxZf2ZleSLcuip7BN2kJIDtucxUgaBy225FrewL59tOxCbj2NRnz_z_CtyUWIAQn5zGjFKGu_7ypjp4pTKiqqKsrFB7JinaxLrtrugqwopW1-C35F1intjmvXso_kirVcKNXWK7LdTmh9720Bzu3tkooZbXwJPqErzKGAYowh2iEGGAoIizfR5d8X8CEthfVpGmDxoRyjyy058_Px9hO57GFIeHOe1-T5_u7v5nf58PTrz-b2obR1x5ZS1IYr04MQQiJywMYYKSTn0Lc9Y10tlWpkI7lSXEmOjVCONaJHJRWAofU1-Xbqneb4b49p0aNPFocBAsZ90m3XMUEblkF2Au0cU5qx19PsR5gPmlF9NKl3OpvUR5OaKp1N5syXc_nejOjeE2d1Gfh6BiBZGPoZQtbxzsma8obLzP04cZhVvHqcdbIeg0Xns-pFu-j_c8YbAMWR4w
CODEN BCPCA6
CitedBy_id crossref_primary_10_1002_mas_20159
crossref_primary_10_1016_j_bcp_2009_02_018
crossref_primary_10_1093_narcan_zcad057
crossref_primary_10_1016_j_jpba_2014_10_017
crossref_primary_10_1016_j_bcp_2011_10_005
crossref_primary_10_3389_fonc_2022_874201
crossref_primary_10_1016_j_dnarep_2018_08_023
crossref_primary_10_1021_tx100023c
crossref_primary_10_1007_s00216_008_2128_3
crossref_primary_10_1021_acs_molpharmaceut_7b00575
crossref_primary_10_1016_j_mrgentox_2011_11_005
crossref_primary_10_1016_j_jasms_2008_12_018
crossref_primary_10_1039_B911438F
Cites_doi 10.1097/00001813-199406000-00010
10.1016/S0076-6879(01)40431-9
10.1093/nar/gkf479
10.1002/ijc.2910620612
10.1023/A:1008355506863
10.1038/bjc.1997.579
10.1002/(SICI)1097-0215(19960503)66:3<404::AID-IJC23>3.0.CO;2-9
10.1007/978-1-4899-0218-4_10
10.1038/bjc.1990.18
10.1083/jcb.200312048
10.1093/carcin/11.12.2117
10.1021/ja00786a045
10.1038/nrd1691
10.1016/S0092-8674(02)00972-8
10.1093/carcin/6.4.561
10.1021/bi973176v
10.1093/carcin/16.10.2447
10.1006/abio.1996.0141
10.1093/carcin/10.12.2367
10.1039/9781847551689-00082
10.1021/ja00470a040
10.1021/bi00361a026
10.1021/bi00324a025
10.1021/bi00285a031
10.1016/S0009-2797(85)80135-6
10.1021/tx000178z
10.1038/bjc.1996.296
ContentType Journal Article
Copyright 2005 Elsevier Inc.
2006 INIST-CNRS
Copyright_xml – notice: 2005 Elsevier Inc.
– notice: 2006 INIST-CNRS
DBID IQODW
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
DOI 10.1016/j.bcp.2005.09.025
DatabaseName Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Chemistry
Pharmacy, Therapeutics, & Pharmacology
EISSN 1873-2968
EndPage 1725
ExternalDocumentID 10_1016_j_bcp_2005_09_025
16259963
17302427
S0006295205006313
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
--K
--M
-~X
.55
.GJ
.HR
.~1
0R~
1B1
1RT
1~.
1~5
23N
3O-
4.4
457
4G.
53G
5GY
5RE
5VS
6J9
7-5
71M
8P~
9JM
AABNK
AACTN
AAEDT
AAEDW
AAIAV
AAIKJ
AAKOC
AALRI
AAOAW
AAQFI
AAQXK
AATCM
AAXUO
AAYJJ
ABFNM
ABFRF
ABJNI
ABLJU
ABMAC
ABXDB
ABYKQ
ABZDS
ACDAQ
ACGFO
ACGFS
ACIUM
ACNCT
ACRLP
ADBBV
ADEZE
ADMUD
AEBSH
AEFWE
AEKER
AENEX
AFFNX
AFKWA
AFTJW
AFXIZ
AGHFR
AGUBO
AGYEJ
AHHHB
AHPSJ
AI.
AIEXJ
AIKHN
AITUG
AJBFU
AJOXV
ALCLG
ALMA_UNASSIGNED_HOLDINGS
AMFUW
AMRAJ
ASPBG
AVWKF
AXJTR
AZFZN
BKOJK
BLXMC
C45
CS3
DU5
EBS
EFJIC
EFLBG
EJD
EO8
EO9
EP2
EP3
F5P
FDB
FEDTE
FGOYB
FIRID
FNPLU
FYGXN
G-2
G-Q
GBLVA
HMT
HVGLF
HZ~
IH2
IHE
J1W
K-O
KOM
L7B
LPU
M34
M41
MO0
N9A
O-L
O9-
OAUVE
OGGZJ
OVD
OZT
P-8
P-9
P2P
PC.
Q38
R2-
RIG
ROL
RPZ
SDF
SDG
SDP
SES
SEW
SPCBC
SPT
SSP
SSZ
T5K
TEORI
TWZ
VH1
WH7
WUQ
X7M
ZA5
ZGI
ZXP
~G-
08R
AAUGY
ABPIF
ABPTK
IQODW
AAXKI
AKRWK
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
ACRPL
ADNMO
AFJKZ
CITATION
7X8
ID FETCH-LOGICAL-c381t-53b29bfa5557ee2ae4bb75722af6f118379947472992972e459d145fe979aab03
IEDL.DBID AIKHN
ISSN 0006-2952
IngestDate Fri Oct 25 09:25:07 EDT 2024
Fri Dec 06 01:59:57 EST 2024
Sat Sep 28 07:57:54 EDT 2024
Sun Oct 22 16:05:48 EDT 2023
Fri Feb 23 02:34:38 EST 2024
IsPeerReviewed true
IsScholarly true
Issue 12
Keywords DNA adduct
Immunoassay
Oligonucleotide
ICP-MS
Ion-exchange chromatography
Cisplatin
Antineoplastic agent
Monoclonal antibody
Inductive coupling plasma spectrometry
Ion exchange chromatography
Immunological method
Alkylating agent
Analysis method
DNA
Mechanism of action
Molecular adduct
Platinum II Complexes
Language English
License CC BY 4.0
https://www.elsevier.com/tdm/userlicense/1.0
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c381t-53b29bfa5557ee2ae4bb75722af6f118379947472992972e459d145fe979aab03
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 16259963
PQID 68815041
PQPubID 23479
PageCount 9
ParticipantIDs proquest_miscellaneous_68815041
crossref_primary_10_1016_j_bcp_2005_09_025
pubmed_primary_16259963
pascalfrancis_primary_17302427
elsevier_sciencedirect_doi_10_1016_j_bcp_2005_09_025
PublicationCentury 2000
PublicationDate 2005-12-05
PublicationDateYYYYMMDD 2005-12-05
PublicationDate_xml – month: 12
  year: 2005
  text: 2005-12-05
  day: 05
PublicationDecade 2000
PublicationPlace New York, NY
PublicationPlace_xml – name: New York, NY
– name: England
PublicationTitle Biochemical pharmacology
PublicationTitleAlternate Biochem Pharmacol
PublicationYear 2005
Publisher Elsevier Inc
Elsevier Science
Publisher_xml – name: Elsevier Inc
– name: Elsevier Science
References Fichtinger-Schepman, van der Veer, den Hartog, Lohman, Reedijk (bib22) 1985; 24
Santella (bib1) 1999; 8
Fichtinger-Schepman, van Dijk-Knijnenburg, van der Velde-Visser, Berends, Baan (bib18) 1995; 16
Eastman (bib30) 1983; 22
Schellens, Ma, Planting, van der Burg, van Meerten, de Boer-Dennert (bib41) 1996; 73
Dijt, Fichtinger-Schepman, Berends, Reedijk (bib32) 1988; 48
Cross, Tilby, Chipman, Ferry, Gescher (bib6) 1996; 66
Peng, Tilby, English, Price, Pearson ADJ, Boddy (bib3) 1997; 76
Hill, Shellard, Fichtinger-Schepman, Schmoll, Harstrick (bib39) 1994; 5
Bonetti, Apostoli, Zaninelli, Pavanel, Colombatti, Cetto (bib42) 1996; 2
Ghazal-Aswad, Tilby, Lind, Baily, Sinha, Calvert (bib4) 1999; 10
Ghazal-Aswad, Calvert, Newell (bib20) 1996; 14
Mellish, Barnard, Murrer, Kelland (bib11) 1995; 62
Kallansrud, Ward (bib19) 1996; 236
Hospers, de Vries, Mulder (bib43) 1990; 61
Deverman, Cook, Manson, Niederhoff, Langer, Rosova (bib9) 2002; 111
Azim-Araghi, Ottley, Pearson, Tilby (bib15) 2002; 43
Reed, Gupta-Burt, Litterst, Poirier (bib25) 1990; 11
Solomon, Cardoso, Knudsen (bib13) 2004; 166
John T, Ottley CJ, Pearson DG, Nowell GM, Calvert AH, Tilby MJ. Determination by ICP-MS, of background and BBR 3464 induced levels of platinum bound to DNA isolated from blood cells: a comparison of the sensitivity of the Perkin-Elmer Sciex Elan 6000 and the ThermoFinnigan Neptune Instruments. In: Plasma source mass spectrometry. Special Publications, Royal Society of Chemistry; 2003. p. 82–90.
Mansy, Chu, Duncan, Tobias (bib29) 1978; 100
Gelasco, Lippard (bib27) 1998; 37
Bedford, Fichtinger-Schepman, Shellard, Walker, Masters, Hill (bib40) 1988; 48
Fichtinger-Schepman, Baan, Luiten-Schuite, van Dijk, Lohman (bib24) 1985; 55
McCartney, Martin, Middleton, Tilby (bib17) 2001; 14
Tilby, Johnson, Knox, Cordell, Roberts, Dean (bib2) 1991; 51
Tilby (bib16) 1992; vol. 10
Veal, Dias, Price, Parry, Errington, Hale (bib5) 2001; 7
Tilby, Styles, Dean (bib21) 1987; 47
Wang, Lippard (bib34) 2005; 4
Azim-Araghi, Ottley, Pearson, Tilby (bib23) 2003
Fichtinger-Schepman, Dijt, Bedford, van Oosterom, Hill, Berends (bib38) 1988; 1987
McGurk, McHugh, Tilby, Grimaldi, Hartley (bib14) 2001; 340
Fichtinger-Schepman, van der Velde-Visser, van Dijk-Knijnenburg, van Oosterom, Baan, Berends (bib33) 1990; 50
Fichtinger-Schepman A-MJ, Welters MJP, van Dijk-Knijnenburg HCM, van der Sterre MLT, Tilby MJ, Berends F, et al. Detection of adducts formed upon treatment of DNA with cisplatin and carboplatin. In: Pinedo HM, Schornagel JH, editors, Platinum and other metal coordination compounds in cancer chemotherapy, vol. 2. Proceedings of the 7th international symposium, Amsterdam, 1995. New York and London: Plenum Press; 1996. p. 107–19.
Fichtinger-Schepman, Baan, Berends (bib26) 1989; 10
Fichtinger-Schepman, van Oosterom, Lohman, Berends (bib37) 1987; 47
De Silva, McHugh, Clingen, Hartley (bib10) 2002; 30
Deverman, Cook, Manson, Niederhoff, Langer, Rosova (bib12) 2002; 111
Mansy, Rosenberg, Thomson (bib28) 1973; 95
Evans, Tilby, Dive (bib7) 1994; 54
Eastman (bib31) 1986; 25
Plooy, Fichtinger-Schepman, Schutte, van Eijk, Lohman (bib36) 1985; 6
Knox, Friedlos, Lydall, Roberts (bib35) 1986; 46
Mansy (10.1016/j.bcp.2005.09.025_bib28) 1973; 95
Schellens (10.1016/j.bcp.2005.09.025_bib41) 1996; 73
Solomon (10.1016/j.bcp.2005.09.025_bib13) 2004; 166
Ghazal-Aswad (10.1016/j.bcp.2005.09.025_bib20) 1996; 14
Mansy (10.1016/j.bcp.2005.09.025_bib29) 1978; 100
10.1016/j.bcp.2005.09.025_bib8
Santella (10.1016/j.bcp.2005.09.025_bib1) 1999; 8
Ghazal-Aswad (10.1016/j.bcp.2005.09.025_bib4) 1999; 10
Bedford (10.1016/j.bcp.2005.09.025_bib40) 1988; 48
Mellish (10.1016/j.bcp.2005.09.025_bib11) 1995; 62
10.1016/j.bcp.2005.09.025_bib44
De Silva (10.1016/j.bcp.2005.09.025_bib10) 2002; 30
Hospers (10.1016/j.bcp.2005.09.025_bib43) 1990; 61
Tilby (10.1016/j.bcp.2005.09.025_bib21) 1987; 47
Reed (10.1016/j.bcp.2005.09.025_bib25) 1990; 11
Fichtinger-Schepman (10.1016/j.bcp.2005.09.025_bib33) 1990; 50
Hill (10.1016/j.bcp.2005.09.025_bib39) 1994; 5
Eastman (10.1016/j.bcp.2005.09.025_bib31) 1986; 25
Peng (10.1016/j.bcp.2005.09.025_bib3) 1997; 76
Deverman (10.1016/j.bcp.2005.09.025_bib12) 2002; 111
Fichtinger-Schepman (10.1016/j.bcp.2005.09.025_bib18) 1995; 16
Gelasco (10.1016/j.bcp.2005.09.025_bib27) 1998; 37
McCartney (10.1016/j.bcp.2005.09.025_bib17) 2001; 14
Eastman (10.1016/j.bcp.2005.09.025_bib30) 1983; 22
Kallansrud (10.1016/j.bcp.2005.09.025_bib19) 1996; 236
Plooy (10.1016/j.bcp.2005.09.025_bib36) 1985; 6
Evans (10.1016/j.bcp.2005.09.025_bib7) 1994; 54
Fichtinger-Schepman (10.1016/j.bcp.2005.09.025_bib22) 1985; 24
Cross (10.1016/j.bcp.2005.09.025_bib6) 1996; 66
Tilby (10.1016/j.bcp.2005.09.025_bib2) 1991; 51
Veal (10.1016/j.bcp.2005.09.025_bib5) 2001; 7
Wang (10.1016/j.bcp.2005.09.025_bib34) 2005; 4
Bonetti (10.1016/j.bcp.2005.09.025_bib42) 1996; 2
Deverman (10.1016/j.bcp.2005.09.025_bib9) 2002; 111
Fichtinger-Schepman (10.1016/j.bcp.2005.09.025_bib26) 1989; 10
Fichtinger-Schepman (10.1016/j.bcp.2005.09.025_bib24) 1985; 55
Tilby (10.1016/j.bcp.2005.09.025_bib16) 1992; vol. 10
Fichtinger-Schepman (10.1016/j.bcp.2005.09.025_bib37) 1987; 47
McGurk (10.1016/j.bcp.2005.09.025_bib14) 2001; 340
Knox (10.1016/j.bcp.2005.09.025_bib35) 1986; 46
Fichtinger-Schepman (10.1016/j.bcp.2005.09.025_bib38) 1988; 1987
Dijt (10.1016/j.bcp.2005.09.025_bib32) 1988; 48
Azim-Araghi (10.1016/j.bcp.2005.09.025_bib15) 2002; 43
Azim-Araghi (10.1016/j.bcp.2005.09.025_bib23) 2003
References_xml – volume: 76
  start-page: 1466
  year: 1997
  end-page: 1473
  ident: bib3
  article-title: Platinum–DNA adduct formation in peripheral blood leucocytes of children in relation to pharmacokinetics following cisplatin and carboplatin therapy
  publication-title: Br J Cancer
  contributor:
    fullname: Boddy
– volume: 24
  start-page: 707
  year: 1985
  end-page: 713
  ident: bib22
  article-title: Adducts of the drug
  publication-title: Biochemistry
  contributor:
    fullname: Reedijk
– volume: 47
  start-page: 1542
  year: 1987
  end-page: 1546
  ident: bib21
  article-title: Immunological detection of DNA damage caused by melphalan using monoclonal antibodies
  publication-title: Cancer Res
  contributor:
    fullname: Dean
– volume: 46
  start-page: 1972
  year: 1986
  end-page: 1979
  ident: bib35
  article-title: Mechanism of cytotoxicity of anticancer platinum drugs: evidence that
  publication-title: Cancer Res
  contributor:
    fullname: Roberts
– volume: 66
  start-page: 404
  year: 1996
  end-page: 408
  ident: bib6
  article-title: Effect of quercetin on the genotoxic potential of cisplatin
  publication-title: Int J Cancer
  contributor:
    fullname: Gescher
– volume: 95
  start-page: 1633
  year: 1973
  end-page: 1640
  ident: bib28
  article-title: Binding of
  publication-title: J Am Chem Soc
  contributor:
    fullname: Thomson
– volume: 5
  start-page: 321
  year: 1994
  end-page: 328
  ident: bib39
  article-title: Differential formation and enhanced removal of specific cisplatin–DNA adducts in two cisplatin-selected resistant human testicular teratoma sublines
  publication-title: Anticancer Drugs
  contributor:
    fullname: Harstrick
– volume: 48
  start-page: 3019
  year: 1988
  end-page: 3024
  ident: bib40
  article-title: Differential repair of platinum–DNA adducts in human bladder and testicular tumor continuous cell lines
  publication-title: Cancer Res
  contributor:
    fullname: Hill
– volume: 8
  start-page: 733
  year: 1999
  end-page: 739
  ident: bib1
  article-title: Immunological methods for detection of carcinogen—DNA damage in humans
  publication-title: Cancer Epidemiol Biomarkers Prev
  contributor:
    fullname: Santella
– volume: 54
  start-page: 1596
  year: 1994
  end-page: 1603
  ident: bib7
  article-title: Differential sensitivity to the induction of apoptosis by cisplatin in proliferating and quiescent immature rat thymocytes is independent of the levels of drug accumulation and DNA adduct formation
  publication-title: Cancer Res
  contributor:
    fullname: Dive
– volume: 16
  start-page: 2447
  year: 1995
  end-page: 2453
  ident: bib18
  article-title: Cisplatin- and carboplatin–DNA adducts: is Pt-AG the cytotoxic lesion?
  publication-title: Carcinogenesis
  contributor:
    fullname: Baan
– volume: 30
  start-page: 3848
  year: 2002
  end-page: 3856
  ident: bib10
  article-title: Defects in interstrand cross-link uncoupling do not account for the extreme sensitivity of ERCC1 and XPF cells to cisplatin
  publication-title: Nucleic Acids Res
  contributor:
    fullname: Hartley
– volume: 61
  start-page: 79
  year: 1990
  end-page: 82
  ident: bib43
  article-title: The formation and removal of cisplatin (CDDP) induced DNA adducts in a CDDP sensitive and resistant human small cell lung carcinoma (HSCLC) cell line
  publication-title: Br J Cancer
  contributor:
    fullname: Mulder
– volume: 48
  start-page: 6058
  year: 1988
  end-page: 6062
  ident: bib32
  article-title: Formation and repair of cisplatin-induced adducts to DNA in cultured normal and repair-deficient human fibroblasts
  publication-title: Cancer Res
  contributor:
    fullname: Reedijk
– volume: 14
  start-page: 71
  year: 2001
  end-page: 81
  ident: bib17
  article-title: Antibody recognition of melphalan adducts characterised using immobilized DNA: enhanced alkylation of G-rich regions in cells compared to in vitro
  publication-title: Chem Res Toxicol
  contributor:
    fullname: Tilby
– volume: 111
  start-page: 51
  year: 2002
  end-page: 62
  ident: bib12
  article-title: Bcl-xL deamidation is a critical switch in the regulation of the response to DNA damage
  publication-title: Cell
  contributor:
    fullname: Rosova
– volume: 111
  start-page: 51
  year: 2002
  end-page: 62
  ident: bib9
  article-title: Bcl-xL deamidation is a critical switch in the regulation of the response to DNA damage
  publication-title: Cell
  contributor:
    fullname: Rosova
– volume: 236
  start-page: 134
  year: 1996
  end-page: 138
  ident: bib19
  article-title: A comparison of measured and calculated single- and double-stranded oligodeoxynucleotide extinction coefficients
  publication-title: Anal Biochem
  contributor:
    fullname: Ward
– volume: 10
  start-page: 2367
  year: 1989
  end-page: 2369
  ident: bib26
  article-title: Influence of the degree of DNA modification on the immunochemical determination of cisplatin–DNA adduct levels
  publication-title: Carcinogenesis
  contributor:
    fullname: Berends
– volume: 7
  start-page: 2205
  year: 2001
  end-page: 2212
  ident: bib5
  article-title: Influence of cellular factors and pharmacokinetics on the formation of platinum–DNA adducts in leucocytes of children receiving cisplatin therapy
  publication-title: Clin Cancer Res
  contributor:
    fullname: Hale
– volume: 100
  start-page: 607
  year: 1978
  end-page: 616
  ident: bib29
  article-title: Heavy metal nucleotide interactions. Part 12: competitive reactions in systems of four nucleotides with
  publication-title: J Am Chem Soc
  contributor:
    fullname: Tobias
– volume: 6
  start-page: 561
  year: 1985
  end-page: 566
  ident: bib36
  article-title: The quantitative detection of various Pt-DNA–adducts in Chinese hamster ovary cells treated with cisplatin: application of immunochemical techniques
  publication-title: Carcinogenesis
  contributor:
    fullname: Lohman
– volume: 4
  start-page: 307
  year: 2005
  end-page: 320
  ident: bib34
  article-title: Cellular processing of platinum anticancer drugs
  publication-title: Nat Rev Drug Discov
  contributor:
    fullname: Lippard
– volume: 47
  start-page: 3000
  year: 1987
  end-page: 3004
  ident: bib37
  article-title:
  publication-title: Cancer Res
  contributor:
    fullname: Berends
– volume: 340
  start-page: 358
  year: 2001
  end-page: 376
  ident: bib14
  article-title: Measurement of covalent drug–DNA interactions at the nucleotide level in cells at pharmacologically relevant doses
  publication-title: Methods Enzymol
  contributor:
    fullname: Hartley
– volume: 50
  start-page: 7887
  year: 1990
  end-page: 7894
  ident: bib33
  article-title: Kinetics of the formation and removal of cisplatin–DNA adducts in blood and tumor tissue of cancer patients receiving chemotherapy: comparison with in vitro adduct formation
  publication-title: Cancer Res
  contributor:
    fullname: Berends
– volume: 51
  start-page: 123
  year: 1991
  end-page: 129
  ident: bib2
  article-title: Sensitive detection of DNA modifications induced by cisplatin and carboplatin in vitro and in vivo using a monoclonal antibody
  publication-title: Cancer Res
  contributor:
    fullname: Dean
– volume: 22
  start-page: 3927
  year: 1983
  end-page: 3933
  ident: bib30
  article-title: Characterization of the adducts produced in DNA by
  publication-title: Biochemistry
  contributor:
    fullname: Eastman
– volume: 10
  start-page: 329
  year: 1999
  end-page: 334
  ident: bib4
  article-title: Pharmacokinetically guided dose escalation of carboplatin in epithelial ovarian cancer: effect on drug-plasma AUC and peripheral blood drug–DNA adduct levels
  publication-title: Ann Oncol
  contributor:
    fullname: Calvert
– volume: 55
  start-page: 275
  year: 1985
  end-page: 288
  ident: bib24
  article-title: Immunochemical quantitation of adducts induced in DNA by
  publication-title: Chem Biol Interact
  contributor:
    fullname: Lohman
– volume: 1987
  start-page: 321
  year: 1988
  end-page: 328
  ident: bib38
  article-title: Induction and removal of cisplatin–DNA adducts in human cells in vivo and in vitro as measured by immunochemical techniques
  publication-title: IARC
  contributor:
    fullname: Berends
– volume: vol. 10
  start-page: 321
  year: 1992
  end-page: 328
  ident: bib16
  article-title: Production of monoclonal antibodies for the detection of chemically modified DNA: methods in molecular biology
  publication-title: Immunochemical protocols
  contributor:
    fullname: Tilby
– volume: 11
  start-page: 2117
  year: 1990
  end-page: 2121
  ident: bib25
  article-title: Characterization of the DNA damage recognised by an antiserum elicited against
  publication-title: Carcinogenesis
  contributor:
    fullname: Poirier
– volume: 166
  start-page: 455
  year: 2004
  end-page: 463
  ident: bib13
  article-title: Dynamic targeting of the replication machinery to sites of DNA damage
  publication-title: J Cell Biol
  contributor:
    fullname: Knudsen
– volume: 37
  start-page: 9230
  year: 1998
  end-page: 9239
  ident: bib27
  article-title: NMR solution structure of a DNA dodecamer duplex containing a
  publication-title: Biochemistry
  contributor:
    fullname: Lippard
– volume: 43
  start-page: 262
  year: 2002
  ident: bib15
  article-title: Structures of atypical platinum–DNA adducts in certain resistant lung cancer lines
  publication-title: Proc Am Assoc Cancer Res
  contributor:
    fullname: Tilby
– volume: 25
  start-page: 3912
  year: 1986
  end-page: 3915
  ident: bib31
  article-title: Re-evaluation of interaction of
  publication-title: Biochemistry
  contributor:
    fullname: Eastman
– volume: 73
  start-page: 1569
  year: 1996
  end-page: 1575
  ident: bib41
  article-title: Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours
  publication-title: Br J Cancer
  contributor:
    fullname: de Boer-Dennert
– volume: 62
  start-page: 717
  year: 1995
  end-page: 723
  ident: bib11
  article-title: DNA-binding properties of novel
  publication-title: Int J Cancer
  contributor:
    fullname: Kelland
– year: 2003
  ident: bib23
  article-title: Combination of ICP-MS and ion exchange chromatography permits analyses of specific cisplatin DNA modifications formed in cancer cells
  publication-title: Plasma source mass spectrometry
  contributor:
    fullname: Tilby
– volume: 2
  start-page: 1829
  year: 1996
  end-page: 1835
  ident: bib42
  article-title: Inductively coupled plasma mass spectroscopy quantitation of platinum–DNA adducts in peripheral blood leukocytes of patients receiving cisplatin- or carboplatin-based chemotherapy
  publication-title: Clin Cancer Res
  contributor:
    fullname: Cetto
– volume: 14
  start-page: 800
  year: 1996
  end-page: 805
  ident: bib20
  article-title: A single-sample assay for the estimation of the area under the free carboplatin plasma concentration versus time curve
  publication-title: Cancer Chemother Pharmacol
  contributor:
    fullname: Newell
– volume: 7
  start-page: 2205
  year: 2001
  ident: 10.1016/j.bcp.2005.09.025_bib5
  article-title: Influence of cellular factors and pharmacokinetics on the formation of platinum–DNA adducts in leucocytes of children receiving cisplatin therapy
  publication-title: Clin Cancer Res
  contributor:
    fullname: Veal
– volume: 5
  start-page: 321
  year: 1994
  ident: 10.1016/j.bcp.2005.09.025_bib39
  article-title: Differential formation and enhanced removal of specific cisplatin–DNA adducts in two cisplatin-selected resistant human testicular teratoma sublines
  publication-title: Anticancer Drugs
  doi: 10.1097/00001813-199406000-00010
  contributor:
    fullname: Hill
– volume: 51
  start-page: 123
  year: 1991
  ident: 10.1016/j.bcp.2005.09.025_bib2
  article-title: Sensitive detection of DNA modifications induced by cisplatin and carboplatin in vitro and in vivo using a monoclonal antibody
  publication-title: Cancer Res
  contributor:
    fullname: Tilby
– volume: 340
  start-page: 358
  year: 2001
  ident: 10.1016/j.bcp.2005.09.025_bib14
  article-title: Measurement of covalent drug–DNA interactions at the nucleotide level in cells at pharmacologically relevant doses
  publication-title: Methods Enzymol
  doi: 10.1016/S0076-6879(01)40431-9
  contributor:
    fullname: McGurk
– volume: 30
  start-page: 3848
  year: 2002
  ident: 10.1016/j.bcp.2005.09.025_bib10
  article-title: Defects in interstrand cross-link uncoupling do not account for the extreme sensitivity of ERCC1 and XPF cells to cisplatin
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gkf479
  contributor:
    fullname: De Silva
– volume: 62
  start-page: 717
  year: 1995
  ident: 10.1016/j.bcp.2005.09.025_bib11
  article-title: DNA-binding properties of novel cis- and trans platinum-based anticancer agents in 2 human ovarian carcinoma cell lines
  publication-title: Int J Cancer
  doi: 10.1002/ijc.2910620612
  contributor:
    fullname: Mellish
– volume: 10
  start-page: 329
  year: 1999
  ident: 10.1016/j.bcp.2005.09.025_bib4
  article-title: Pharmacokinetically guided dose escalation of carboplatin in epithelial ovarian cancer: effect on drug-plasma AUC and peripheral blood drug–DNA adduct levels
  publication-title: Ann Oncol
  doi: 10.1023/A:1008355506863
  contributor:
    fullname: Ghazal-Aswad
– year: 2003
  ident: 10.1016/j.bcp.2005.09.025_bib23
  article-title: Combination of ICP-MS and ion exchange chromatography permits analyses of specific cisplatin DNA modifications formed in cancer cells
  contributor:
    fullname: Azim-Araghi
– volume: 76
  start-page: 1466
  year: 1997
  ident: 10.1016/j.bcp.2005.09.025_bib3
  article-title: Platinum–DNA adduct formation in peripheral blood leucocytes of children in relation to pharmacokinetics following cisplatin and carboplatin therapy
  publication-title: Br J Cancer
  doi: 10.1038/bjc.1997.579
  contributor:
    fullname: Peng
– volume: 66
  start-page: 404
  year: 1996
  ident: 10.1016/j.bcp.2005.09.025_bib6
  article-title: Effect of quercetin on the genotoxic potential of cisplatin
  publication-title: Int J Cancer
  doi: 10.1002/(SICI)1097-0215(19960503)66:3<404::AID-IJC23>3.0.CO;2-9
  contributor:
    fullname: Cross
– volume: vol. 10
  start-page: 321
  year: 1992
  ident: 10.1016/j.bcp.2005.09.025_bib16
  article-title: Production of monoclonal antibodies for the detection of chemically modified DNA: methods in molecular biology
  contributor:
    fullname: Tilby
– ident: 10.1016/j.bcp.2005.09.025_bib8
  doi: 10.1007/978-1-4899-0218-4_10
– volume: 61
  start-page: 79
  year: 1990
  ident: 10.1016/j.bcp.2005.09.025_bib43
  article-title: The formation and removal of cisplatin (CDDP) induced DNA adducts in a CDDP sensitive and resistant human small cell lung carcinoma (HSCLC) cell line
  publication-title: Br J Cancer
  doi: 10.1038/bjc.1990.18
  contributor:
    fullname: Hospers
– volume: 166
  start-page: 455
  year: 2004
  ident: 10.1016/j.bcp.2005.09.025_bib13
  article-title: Dynamic targeting of the replication machinery to sites of DNA damage
  publication-title: J Cell Biol
  doi: 10.1083/jcb.200312048
  contributor:
    fullname: Solomon
– volume: 54
  start-page: 1596
  year: 1994
  ident: 10.1016/j.bcp.2005.09.025_bib7
  article-title: Differential sensitivity to the induction of apoptosis by cisplatin in proliferating and quiescent immature rat thymocytes is independent of the levels of drug accumulation and DNA adduct formation
  publication-title: Cancer Res
  contributor:
    fullname: Evans
– volume: 11
  start-page: 2117
  year: 1990
  ident: 10.1016/j.bcp.2005.09.025_bib25
  article-title: Characterization of the DNA damage recognised by an antiserum elicited against cis-diamminedichloroplatinum(II)-modified DNA
  publication-title: Carcinogenesis
  doi: 10.1093/carcin/11.12.2117
  contributor:
    fullname: Reed
– volume: 95
  start-page: 1633
  year: 1973
  ident: 10.1016/j.bcp.2005.09.025_bib28
  article-title: Binding of cis- and trans-dichlorodiammineplatinum(II) to nucleosides. Part I: location of the binding sites
  publication-title: J Am Chem Soc
  doi: 10.1021/ja00786a045
  contributor:
    fullname: Mansy
– volume: 2
  start-page: 1829
  year: 1996
  ident: 10.1016/j.bcp.2005.09.025_bib42
  article-title: Inductively coupled plasma mass spectroscopy quantitation of platinum–DNA adducts in peripheral blood leukocytes of patients receiving cisplatin- or carboplatin-based chemotherapy
  publication-title: Clin Cancer Res
  contributor:
    fullname: Bonetti
– volume: 47
  start-page: 3000
  year: 1987
  ident: 10.1016/j.bcp.2005.09.025_bib37
  article-title: cis-Diamminedichloroplatinum(II)-induced DNA adducts in peripheral leukocytes from seven cancer patients: quantitative immunochemical detection of the adduct induction and removal after a single dose of cis-diamminedichloroplatinum(II)
  publication-title: Cancer Res
  contributor:
    fullname: Fichtinger-Schepman
– volume: 4
  start-page: 307
  year: 2005
  ident: 10.1016/j.bcp.2005.09.025_bib34
  article-title: Cellular processing of platinum anticancer drugs
  publication-title: Nat Rev Drug Discov
  doi: 10.1038/nrd1691
  contributor:
    fullname: Wang
– volume: 111
  start-page: 51
  year: 2002
  ident: 10.1016/j.bcp.2005.09.025_bib9
  article-title: Bcl-xL deamidation is a critical switch in the regulation of the response to DNA damage
  publication-title: Cell
  doi: 10.1016/S0092-8674(02)00972-8
  contributor:
    fullname: Deverman
– volume: 6
  start-page: 561
  year: 1985
  ident: 10.1016/j.bcp.2005.09.025_bib36
  article-title: The quantitative detection of various Pt-DNA–adducts in Chinese hamster ovary cells treated with cisplatin: application of immunochemical techniques
  publication-title: Carcinogenesis
  doi: 10.1093/carcin/6.4.561
  contributor:
    fullname: Plooy
– volume: 46
  start-page: 1972
  year: 1986
  ident: 10.1016/j.bcp.2005.09.025_bib35
  article-title: Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA
  publication-title: Cancer Res
  contributor:
    fullname: Knox
– volume: 37
  start-page: 9230
  year: 1998
  ident: 10.1016/j.bcp.2005.09.025_bib27
  article-title: NMR solution structure of a DNA dodecamer duplex containing a cis-diammineplatinum(II) d(GpG) intrastrand cross-link, the major adduct of the anticancer drug cisplatin
  publication-title: Biochemistry
  doi: 10.1021/bi973176v
  contributor:
    fullname: Gelasco
– volume: 16
  start-page: 2447
  year: 1995
  ident: 10.1016/j.bcp.2005.09.025_bib18
  article-title: Cisplatin- and carboplatin–DNA adducts: is Pt-AG the cytotoxic lesion?
  publication-title: Carcinogenesis
  doi: 10.1093/carcin/16.10.2447
  contributor:
    fullname: Fichtinger-Schepman
– volume: 236
  start-page: 134
  year: 1996
  ident: 10.1016/j.bcp.2005.09.025_bib19
  article-title: A comparison of measured and calculated single- and double-stranded oligodeoxynucleotide extinction coefficients
  publication-title: Anal Biochem
  doi: 10.1006/abio.1996.0141
  contributor:
    fullname: Kallansrud
– volume: 10
  start-page: 2367
  year: 1989
  ident: 10.1016/j.bcp.2005.09.025_bib26
  article-title: Influence of the degree of DNA modification on the immunochemical determination of cisplatin–DNA adduct levels
  publication-title: Carcinogenesis
  doi: 10.1093/carcin/10.12.2367
  contributor:
    fullname: Fichtinger-Schepman
– volume: 47
  start-page: 1542
  year: 1987
  ident: 10.1016/j.bcp.2005.09.025_bib21
  article-title: Immunological detection of DNA damage caused by melphalan using monoclonal antibodies
  publication-title: Cancer Res
  contributor:
    fullname: Tilby
– volume: 48
  start-page: 3019
  year: 1988
  ident: 10.1016/j.bcp.2005.09.025_bib40
  article-title: Differential repair of platinum–DNA adducts in human bladder and testicular tumor continuous cell lines
  publication-title: Cancer Res
  contributor:
    fullname: Bedford
– volume: 50
  start-page: 7887
  year: 1990
  ident: 10.1016/j.bcp.2005.09.025_bib33
  article-title: Kinetics of the formation and removal of cisplatin–DNA adducts in blood and tumor tissue of cancer patients receiving chemotherapy: comparison with in vitro adduct formation
  publication-title: Cancer Res
  contributor:
    fullname: Fichtinger-Schepman
– ident: 10.1016/j.bcp.2005.09.025_bib44
  doi: 10.1039/9781847551689-00082
– volume: 100
  start-page: 607
  year: 1978
  ident: 10.1016/j.bcp.2005.09.025_bib29
  publication-title: J Am Chem Soc
  doi: 10.1021/ja00470a040
  contributor:
    fullname: Mansy
– volume: 111
  start-page: 51
  year: 2002
  ident: 10.1016/j.bcp.2005.09.025_bib12
  article-title: Bcl-xL deamidation is a critical switch in the regulation of the response to DNA damage
  publication-title: Cell
  doi: 10.1016/S0092-8674(02)00972-8
  contributor:
    fullname: Deverman
– volume: 25
  start-page: 3912
  year: 1986
  ident: 10.1016/j.bcp.2005.09.025_bib31
  article-title: Re-evaluation of interaction of cis- dichloro(ethylenediamine)platinum(II) with DNA
  publication-title: Biochemistry
  doi: 10.1021/bi00361a026
  contributor:
    fullname: Eastman
– volume: 1987
  start-page: 321
  year: 1988
  ident: 10.1016/j.bcp.2005.09.025_bib38
  article-title: Induction and removal of cisplatin–DNA adducts in human cells in vivo and in vitro as measured by immunochemical techniques
  publication-title: IARC
  contributor:
    fullname: Fichtinger-Schepman
– volume: 8
  start-page: 733
  year: 1999
  ident: 10.1016/j.bcp.2005.09.025_bib1
  article-title: Immunological methods for detection of carcinogen—DNA damage in humans
  publication-title: Cancer Epidemiol Biomarkers Prev
  contributor:
    fullname: Santella
– volume: 43
  start-page: 262
  year: 2002
  ident: 10.1016/j.bcp.2005.09.025_bib15
  article-title: Structures of atypical platinum–DNA adducts in certain resistant lung cancer lines
  publication-title: Proc Am Assoc Cancer Res
  contributor:
    fullname: Azim-Araghi
– volume: 24
  start-page: 707
  year: 1985
  ident: 10.1016/j.bcp.2005.09.025_bib22
  article-title: Adducts of the drug cis-diamminedichloroplatinum(II) with DNA: formation, identification and quantitation
  publication-title: Biochemistry
  doi: 10.1021/bi00324a025
  contributor:
    fullname: Fichtinger-Schepman
– volume: 22
  start-page: 3927
  year: 1983
  ident: 10.1016/j.bcp.2005.09.025_bib30
  article-title: Characterization of the adducts produced in DNA by cis-diamminedichloroplatinum(II) and cis-dichloro(ethylenediamine)platinum(II)
  publication-title: Biochemistry
  doi: 10.1021/bi00285a031
  contributor:
    fullname: Eastman
– volume: 55
  start-page: 275
  year: 1985
  ident: 10.1016/j.bcp.2005.09.025_bib24
  article-title: Immunochemical quantitation of adducts induced in DNA by cis-diamminedichloroplatinum(II) and analysis of adduct-related DNA-unwinding
  publication-title: Chem Biol Interact
  doi: 10.1016/S0009-2797(85)80135-6
  contributor:
    fullname: Fichtinger-Schepman
– volume: 14
  start-page: 71
  year: 2001
  ident: 10.1016/j.bcp.2005.09.025_bib17
  article-title: Antibody recognition of melphalan adducts characterised using immobilized DNA: enhanced alkylation of G-rich regions in cells compared to in vitro
  publication-title: Chem Res Toxicol
  doi: 10.1021/tx000178z
  contributor:
    fullname: McCartney
– volume: 14
  start-page: 800
  year: 1996
  ident: 10.1016/j.bcp.2005.09.025_bib20
  article-title: A single-sample assay for the estimation of the area under the free carboplatin plasma concentration versus time curve
  publication-title: Cancer Chemother Pharmacol
  contributor:
    fullname: Ghazal-Aswad
– volume: 48
  start-page: 6058
  year: 1988
  ident: 10.1016/j.bcp.2005.09.025_bib32
  article-title: Formation and repair of cisplatin-induced adducts to DNA in cultured normal and repair-deficient human fibroblasts
  publication-title: Cancer Res
  contributor:
    fullname: Dijt
– volume: 73
  start-page: 1569
  year: 1996
  ident: 10.1016/j.bcp.2005.09.025_bib41
  article-title: Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours
  publication-title: Br J Cancer
  doi: 10.1038/bjc.1996.296
  contributor:
    fullname: Schellens
SSID ssj0006861
Score 1.9260932
Snippet Numerous clinical or experimental studies have employed monoclonal antibody CP9/19 for quantification of cisplatin DNA adducts. The nature of adducts...
SourceID proquest
crossref
pubmed
pascalfrancis
elsevier
SourceType Aggregation Database
Index Database
Publisher
StartPage 1717
SubjectTerms Antibodies, Monoclonal - immunology
Antineoplastic agents
Biological and medical sciences
Chromatography, Ion Exchange
Cisplatin
Cisplatin - metabolism
DNA adduct
DNA Adducts - analysis
DNA Adducts - immunology
Enzyme-Linked Immunosorbent Assay
General aspects
Humans
ICP-MS
Immunoassay
Ion-exchange chromatography
Medical sciences
Oligodeoxyribonucleotides - immunology
Oligonucleotide
Pharmacology. Drug treatments
Title Specific adducts recognised by a monoclonal antibody against cisplatin-modified DNA
URI https://dx.doi.org/10.1016/j.bcp.2005.09.025
https://www.ncbi.nlm.nih.gov/pubmed/16259963
https://search.proquest.com/docview/68815041
Volume 70
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELZKewAJISiPLo_FB9QDqtvE6-dxtVAtIFaVaKXeLDuxURBNIrJ72Au_nXHisKoEHLhamsTyZ30zY4_nQ-hN5kXJg9REWRUIE_GgiVpJuMsZ5G5U2r6l0OeVWF6xj9f8eg8txrcwsawycf_A6T1bp5GztJpnbVXFN76ZoJrTjEc_G5VrD8Adxbvag_mHT8vVb0IWSiThPEGiwXi52Zd5uaJNJyv6NIuC2X92T_db28GihUHt4u_haO-Wzh-iBymexPNhyo_Qnq8P0d3FKON2iI4vhubU2xN8uXtr1Z3gY3yxa1u9fYy-9FL0oSowkNGmWHc4FRd1vsRuiy2GHdsU32PojgGPyjUljH61FUSYGKbbxrK6mtw0JXwFbN6t5k_Q1fn7y8WSJMkFUoDrXhM-c1S7YDnn0ntqPXNOckmpDSJALjKTWjPIQMCJUS2pZ1yXOYsFa1Jb67LZU7RfN7U_Qlh5IVhQTpXFjFHpwO1ZqnxeFJnyIecT9HZcadMOnTXMWHL2zQAsUSGTm0wbgGWC2IiFubU9DDD_v8ymt3Db_QiIDYITOUGvRyAN4BIvS2ztm01nhFIQK7N8gp4N-O5sY8oIvPX8_-b0At0b2r9SkvGXaH_9Y-NfQWCzdlN05_RnPk3b9xfZIPXR
link.rule.ids 314,780,784,4502,24116,27924,27925,45585,45679
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La9wwEBYhOaRQQpu-to9Eh5JDiRtbq-dx2TZsmmQJdAO5CcmWikNim3r3sP--I1vuEmhy6FUwttCIb76RRvMh9Dl1vGBeqEQa6RPKw0ETMSJhNqOQuxFhupZCl3M-u6Y_btjNFpoOb2FCWWXE_h7TO7SOIydxNU-asgxvfFNOFCMpC3E2KNfuABsQsLV3Jmfns_lfQOaSR-E8ngSD4XKzK_OyeRNPVtTXNAhm_zs8PW9MC4vme7WLx-loF5ZOX6C9yCfxpJ_yS7Tlqn20Ox1k3PbR0VXfnHp9jBebt1btMT7CV5u21etX6GcnRe_LHAMYrfJli2NxUesKbNfYYNixdX4XqDsGf5S2LmD0lymBYWKYbhPK6qrkvi7gK2DzbT55ja5Pvy-msyRKLiQ5hO5lwsaWKOsNY0w4R4yj1gomCDGee8hFxkIpChkIBDGiBHGUqSKjoWBNKGNsOn6Dtqu6cu8Qlo5z6qWVRT6mRFgIe4ZIl-V5Kp3P2Ah9GVZaN31nDT2UnN1qcEtQyGQ6VRrcMkJ08IV-sD00IP9TZgcP_Lb5EQAbkBMxQoeDIzX4JVyWmMrVq1ZzKYEr02yE3vb-3diGlBFw6_3_zekQ7c4Wlxf64mx-_gE961vBkiRlH9H28vfKfQKSs7QHcRP_AeUI984
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Specific+adducts+recognised+by+a+monoclonal+antibody+against+cisplatin-modified+DNA&rft.jtitle=Biochemical+pharmacology&rft.au=Meczes%2C+Emma+L&rft.au=Azim-Araghi%2C+Ali&rft.au=Ottley%2C+Christopher+J&rft.au=Pearson%2C+D+Graham&rft.date=2005-12-05&rft.issn=0006-2952&rft.volume=70&rft.issue=12&rft.spage=1717&rft_id=info:doi/10.1016%2Fj.bcp.2005.09.025&rft_id=info%3Apmid%2F16259963&rft.externalDocID=16259963
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0006-2952&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0006-2952&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0006-2952&client=summon